A. Introduction
It is becoming increasingly clear that chemical, physical, and biologic carcinogens are immunosuppressive. Most of the available information on the immunosuppressive activity of oncogenic agents concerns adaptive immunity [17] . Recent studies have indicated that exposure of laboratory animals to various carcinogenic insults affected also certain expressions of innate, natural immunity such as natural killer (NK) activity (for review see [2] ).
In previous studies, we demonstrated that the chemical carcinogen dimethylbenzanthracene (DMBA) exerted a severe suppressive effect on NK activity of mouse splenocytes [3, 4] . In the present study, we addressed the following questions:
1. Is the decrease in NK activity of DMBA-treated mice restricted to the spleen, or is this decrease also evident in other lymphocyte-containing compartments? To answer this question, we compared the NK activity of peripheral blood leukocytes (PBL) from untreated and DMBA-treated mice. We also performed adoptive transfer experiments in which we tested the NK activity of splenocytes from lethally irradiated recipients reconstituted with syngeneic bone marrow from either untreated or from DMBA-treated donors. 2. Is the decrease in NK activity of DMBA-treated animals due to a functional defect or is it due to a reduction in the size of the NK cell population? This was answered in the present study by performing a flow cytometry analysis of cells expressing asialo-GM-I-(a ganglioside expressed on the membrane of certain lymphocyte subpopulations, especially NK cells [7] ), in the spleen ofDMBA-treated animals.
3. Are other cells of the immune system also affected by DMBA? We have begun to answer this by performing mixed lymphocyte reactions (MLR) in which lymphocytes of DMBA-treated animals served as responders.
4. Is the activity of natural antitumor antibodies (NATA) affected by carcinogen treatment? We have compared NATA activity of untreated mice with that of urethane-or DMBA-treated ones.
B. Results
I. The NKActivity ofPBL from DMBATreated BALB/c Mice Table I shows that the NK activity of PBL from DMBA-treated BALB/c mice is considerably lower than that of untreated ageand sex-matched syngeneic controls. These results indicate that the effect of DMBA on Table 2 indicate that DMBA treatment, under the experimental conditions utilized in this study, impaired the ability of bone marrow precursors to reconstitute NK activity in lethally irradiated recipients.
In order to find out whether or not DMBA was selectively toxic toward lymphatic cells such as NK cells, we compared spleen colonies of irradiated mice which received an adoptive transfer of bone marrow cells either from DMBA-treated mice or from untreated controls. We detected no qualitative or quantitative differences between the two groups. DMBA also failed to affect the ability of bone marrow cells to produce colonies in soft agar. These results suggest that DMBA acts selectively on lymphocyte precursors in the bone marrow.
III. Flow Cytometry Analysis of Splenocytes from DMBA-Treated BALB/c Mice
The percentage of Thy-I, Lyt-l, Lyt-2, and asialo-GM-I-positive cells in the spleen of untreated or DMBA-treated animals was determined by flow cytometry using commercially available fluorescently tagged antibodies. The results presented in Table 3 indicate that the percentage of the total T cell population and the two major T cell subpopulations were not affected by DMBA. The percentage of asialo-GM-I-positive NK cells was however drastically reduced. It should be remembered that the size of the spleen in DMBA-treated mice was reduced by about 50% [4] . The absolute number of T cells in the spleen was therefore reduced by the same factor whereas that of asialo-GM-I-positive cells was reduced by a much larger factor. These results suggest that DMBA was selectively toxic toward asialo-GM-I-positive cells with NK activity. However, sorting of asialo GM-I positive cells originating in spleens or PBL of control or DMBA-treated animals (results not shown) indicated that the decreased NK activity observed in the Table 1 ) d Cells were directly stained with FITC-conjugated monoclonal antibody directed against the appropriate marker e Cells were first treated with rabbit IgG directed against asialo-GM-I and then stained with FITC-conjugated affinity-purified goat antibody against rabbit IgG Table 2 latter mice was due to a reduction in the size of the NK cell population rather than to a functional defect of these cells.
IV. The Ability ofT Cells from DMBATreated BALB/c Mice to Respond in the Mixed Lymphocyte Reaction
As we have seen, the marker analysis of splenic T cells of DMBA-treated mice showed no difference between the treated mice and untreated controls. We carried out experiments to find out whether DMBA, while not affecting the number of T cell populations, had some effects on their responder function in MLR. The results of assays in which splenocytes from DMBA-treated or from untreated BALB/c (H-2 d ) mice were allowed to react against C3HI eB(H-2~ antigens, are given in Table  4 . It was shown that DMBA administration reduced the ability of BALB/c mice to respond to the assayed alloantigens by an average of 50%.
Adoptive transfer experiments in which bone marrow from untreated or from DMBA-treated animals was transferred to lethally irradiated recipients were performed. The results of these experiments indicated ( Table 4 ) that bone marrow precursors were also affected by D MBA in their capacity to reconstitute MLR responder activity.
V. Lymphoma-Reactive Natural Antibodies in Untreated and in CarcinogenTreated BALB/c Mice In a previous study [19] we found that sera from young normal BALB/c mice contain IgM antibodies able to mediate complement-dependent lysis of certain syngeneic or allogeneic tumor target cells. The titer of such naturally occurring antitumor antibodies (NATA) was found to increase with aging.
A longitudinal serologic study comparing the cytotoxicity potential of NATA from normal and from urethane-treated BALB/c mice was performed. It was found that urethane-treated mice that did not develop primary lung adenomas within the duration of the experiment had significantly lower NATA titers against the L5178-Y lymphoma than urethane-treated animals that developed lung adenomas. This difference was evident in two independent experiments. The results suggested that the lower antibody activity of the urethanetreated mice that did not develop tumors existed even before exposure to the carcinogenic insult. The results of preliminary experiments suggest that a similar situation also exists with DMBA carcinogenesis. These findings raise the possibility that certain populations could be segregated according to their natural antibody profile into those individuals which will develop primary tumors within a certain period if exposed to a subthreshold amount of carcinogen, and those which will not. Furthermore, the results indicated that these naturally occurring lymphoma-reactive antibodies may play a biologic role in the development of certain primary tumors. In order to study these antibodies and the antigens they react with, we prepared hybridomas from lymphocytes of LPSstimulated, but otherwise untreated BALB/c mice. These hybridomas were screened for secretion of antibodies which bind to L5178-Y lymphoma cells. Some binding characteristics of five of the L5178-Y lymphoma-reactive natural monoclonals are given in Table 5 . It can be seen that two of the five natural hybridomas secrete antibodies which bind primarily to lymphoid tissues.
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C. Discussion
Natural defense mechanisms are considered by several investigators to be the first line of defense against developing neoplasia [10] . If this is indeed the case, then suppression of such defense mechanisms, for example by cancer-inducing agents, might enhance the proliferation and progression of transformed cells toward a fully fledged malignancy. There are numerous investigations showing that exposure to cancer-inducing agents such as chemicals [4] , irradiation [8, 15] , or hormones [12] causes a depression in one or more of the expressions of natural immunity.
The major part of the present study is an extension of previous findings, showing that the chemical carcinogen DMBA causes a severe suppression of NK activity shortly after administration and long before the appearance of palpable tumors [4] . In this study, we demonstrated that the effect is systemic and that bone marrow precursors are affected. The results also proved that the decreased NK activity was due to a selective toxic effect toward NK precursors and perhaps also to mature NK (asialo-GM-I-positive cells), but not due to a functional defect of such cells. We do not know, as yet, if the NK deficiency of DMBA-treated mice contributes toward tumor development.
The mode of induction of naturally occurring-antibodies, their physiologic role, and the mechanisms regulating their levels and functions are largely unknown.
It seems that the repertoire of naturally occurring antibodies is rather large, equaling perhaps that of adaptively induced antibodies. Among the epitopes recognized by naturally occurring antibodies are many expressed on normal cells [6, 21] , on malignant cells [13, 14] , or on various oncoviruses [9, 16] . None of these epitopes is restricted to these cells or viruses. However, even in this situation, naturally reacting antibodies directed against epitopes expressed on malignant cells could function as regulators of the progression of malignancy. This could occur at several levels by various mechanisms such as binding to and neutralization of oncogenic viruses [1, 11] , opsonizing transformed or nascent malignant cells, lysing them by complement activation, or arming of naturally occurring Fc receptor-positive killer immunocytes [18, 20] . It is also possible that natural antibodies may enhance tumor growth and development by direct or indirect mechanisms [5] . Our previous studies suggested that certain lymphoma-reactive natural antibodies may playa role in chemical car-. . cmogenesls.
The characterization of these antibodies is an essential prerequisite in order to establish the physiologic function of such antibodies and the role they play in controlling primary tumor development. Establishing hybridomas secreting tumor-reactive antibodies is the first step toward this goal. 
